Published January 2009

This practice parameter provides recommendations for the role of laboratory and genetic tests in the evaluation of distal symmetric polyneuropathy (DSP) based upon a prescribed review and analysis of the peer-reviewed literature.  Reaffirmed on January 22, 2022.

Published March 2015

The objective of this guideline is to delineate optimal diagnostic and therapeutic approaches to congenital muscular dystrophy (CMD) through a systematic review and analysis of the currently available literature. Reaffirmed on July 12, 2024. Co-developed with the American Association of Neuromuscu

Published October 2014

This guideline reviews the current evidence and makes practice recommendations regarding the diagnosis and treatment of LGMDs. Reaffirmed on April 30, 2022. Codeveloped with the American Association of Neuromuscular & Electrodiagnostic Medicine. Endorsed by the American Academy of Physical Medicin

Published January 2005

The objective of this report was to develop a case definition of distal symmetric polyneuropathy to standardize and facilitate clinical research and epidemiologic studies. Reaffirmed on October 19, 2024.

Published September 2003

This practice parameter classifies the relevant evidence on immunotherapy to provide evidence-based recommendations for the management of GBS. Reaffirmed on January 22, 2022.

Published March 2003

This assessment evaluates the clinical utility, efficacy, and safety of quantitative sensory testing (QST). Reaffirmed on January 22, 2022.

Published February 2010

Physicians are faced with a difficult scenario in choosing a treatment regimen for patients with muscle cramps. This American Academy of Neurology assessment systematically reviews the available evidence on the symptomatic treatment of muscle cramps. Reaffirmed on July 16, 2022. Endorsed by the Am

Published March 2020

Reaffirmed on July 14, 2023. This practice advisory reviews updated evidence regarding the effectiveness of thymectomy for treating patients with myasthenia gravis.

Published October 2009

This article addresses riluzole, lithium, nutrition, and respiratory care, while a companion article addresses breaking the news, symptom management, palliative care, cognitive and behavioral impairment, multidisciplinary clinics, and communication. Reaffirmed on January 25, 2023. Endorsed by the

Published February 2016

A 2005 American Academy of Neurology (AAN) guideline on the use of corticosteroids in patients with Duchenne muscular dystrophy (DMD) recommended prednisone or deflazacort in the treatment of DMD for short-term benefit in muscle strength and function. There are currently variations in practice in co

Published July 2015

The goal of this guideline was to develop recommendations for the evaluation, diagnosis, prognostication, and treatment of facioscapulohumeral muscular dystrophy (FSHD) from a systematic review and analysis of the evidence. Reaffirmed on July 12, 2024. Codeveloped with the American Association of

Published February 2012

Last reaffirmed on October 21, 2023. Endorsed by the American Association of Neuromuscular and Electrodiagnostic Medicine.

Published December 2021

This guideline updates the 2011 AAN practice guideline on the treatment of painful diabetic neuropathy. For patients with painful diabetic neuropathy, clinicians should review all of the available options to reduce pain, including oral, topical, and nonpharmacologic interventions. It is important fo

Published October 2009

In this guideline we systematically reviewed evidence bearing on the management of patients with amyotrophic lateral sclerosis (ALS). Reaffirmed on February 25, 2023. Endorsed by the American Association of Neuromuscular and Electrodiagnostic Medicine.